Cyproterone
Clinical data | |
---|---|
Other names | SH-80881; SH-881; NSC-758636; 1α,2α-Methylene-6-chloro-17α-hydroxy-δ6-progesterone; 1α,2α-Methylene-6-chloro-17α-hydroxypregna-4,6-diene-3,20-dione |
Routes of administration | By mouth, topical |
Drug class | Steroidal antiandrogen |
ATC code | |
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Cyproterone, also known by its developmental code name SH-80881, is a
It is important to clarify that the term cyproterone is often used as a synonym and shorthand for cyproterone acetate, and when the term occurs, what is almost always being referred to is, confusingly, CPA and not actually cyproterone. Cyproterone itself, unlike CPA, was never introduced for medical use and hence is not available as a medication.
Pharmacology
Pharmacodynamics
Antiandrogenic activity
Cyproterone is a potent antiandrogen, similarly to CPA.
Due to its progonadotropic effects in males, unlike CPA, cyproterone has been found, in male rodents, to increase
Other activities
Both CPA and, to a smaller extent, cyproterone possess some weak
Chemistry
Cyproterone, also known as 1α,2α-methylene-6-chloro-17α-hydroxy-δ6-progesterone or as 1α,2α-methylene-6-chloro-17α-hydroxypregna-4,6-diene-3,20-dione, is a
History
Cyproterone, along with CPA, was first patented in 1962,[18] with subsequent patents in 1963 and 1965.[1] It was studied clinically between 1967 and 1972.[19][20] Unlike CPA, the medication was never marketed for medical use.[1][2] Cyproterone was the first pure antiandrogen to be developed,[21] with other closely following examples of this class including the steroidal antiandrogens benorterone and BOMT and the nonsteroidal antiandrogen flutamide.[4]
Society and culture
Generic names
Cyproterone is the
.Research
In clinical studies, cyproterone was found to be far less potent and effective as an antiandrogen than CPA, likely in significant part due to its lack of concomitant antigonadotropic action.[3] Cyproterone was studied as a treatment for precocious puberty by Bierich (1970, 1971), but no significant improvement was observed.[22] In men, 100 mg/day cyproterone proved to be rather ineffective in treating acne, which was hypothesized to be related to its progonadotropic effects in males and counteraction of its antiandrogen activity.[3][23] In women however, who have much lower levels of testosterone and in whom the medication has no progonadotropic activity, 100 to 200 mg/day oral cyproterone was effective in reducing sebum production in all patients as early as 2 to 4 weeks following the start of treatment.[3] In contrast, topical cyproterone was far less effective and barely outperformed placebo.[3]
Another study showed disappointing results with 100 mg/day cyproterone for reducing sebum production in women with
References
- ^ ISBN 978-1-4757-2085-3.
- ^ ISBN 978-3-88763-075-1. Retrieved 29 May 2012.
- ^ ISBN 978-3-642-74612-3.
- ^ ISBN 978-1-60761-471-5.
The progestational effect [of CPA] is linked to the presence of the acetyl group at position C17 of the steroid. Consequently, the free alcohol of CPA, cyproterone, which lacks the acetyl group, is devoid of progestational properties. However, it still exerts antiandrogenic activity, although less pronounced than CPA. Consequently, cyproterone was the first compound falling into the nowadays well-known class of pure antiandrogens.
- ^ ISSN 0105-6263.
[...] Hammerstein 1977). This consideration is based on the fact that free cyproterone is a potent anti- androgen without antigonadotrophic activity and causes, therefore, an increase in gonadotrophins and in androgens (Graf et al. 1974). In [...]
- ^ PMID 4125095.
Cyproterone (6-chloro-17-hydroxy-1,2α-methylenepregna-4,6-diene-3,20-dione) and cyproterone acetate (17-acetoxy-6-chloro-1,2α-methylene-pregna-4,6-diene-3,20-dione) are powerful anti-androgens, which exert multiple actions in many species. Cyproterone acetate has three times the anti-androgenic potency of cyproterone, and also has some progestational properties (for review, see Neumann et al., 1970). [...] Cyproterone seemed to decrease the activity of 17α-hydroxysteroid dehydrogenase and of 5α-steroid reductase in human prostate in vitro, as it does in testes and liver of rats (Breuer & Hoffmann, 1967; Hoffmann & Breuer, 1968; Denef et al., 1968). Cyproterone acetate did not seem to have any direct effect on the activity of these two enzymes.
- ISBN 978-0-520-01887-7.
- ^ ISBN 978-3-642-80859-3.
The only chemical difference between cyproterone and cyproterone acetate consists of a free or esterified hydroxyl group at C17 but this difference accounts for profound differences in the mechanism of action and possibilities for use in the intact organism. Both steroids are highly active antiandrogens at any route of administration, the acetate has a greater antiandrogenic potency than the free alcohol. With the exception of a slight depressive effect on the adrenals, cyproterone does not have other side-activities unrelated to antiandrogenicity. It has, therefore, been termed "pure antiandrogen". Cyproterone acetate has one major additional activity: it is one of the strongest gestagens that have ever been synthesized [23, 70, 32, 77], [...]
- ISBN 978-3-642-81652-9.
Contrary to benorterone, free cyproterone, and flutamide, CPA is not a pure anti- androgen. In fact, it is one of the most potent progestogens known and, in comparison to that potency, it is a relatively weak antiandrogen and a still weaker anti- gonadotropin.
- S2CID 30486799.
Cyproterone which has a very weak biological progestogen potency exhibited low affinity for the progestogen-receptor (Table I).
- ^ ISBN 978-3-642-96158-8.
Cyproterone acetate is 250 and 3330 times as potent a progestational agent as progesterone and cyproterone alcohol (10< respectively (Clauberg assay). [...] The pure anti-androgens, such as cyproteron, block the receptors of the negative feedback system. An uninhibited secretion of the releasing factors and an increased production of gonadotropins results, so that the inhibitory effect on the endorgans may finally be overcome by overpoduction of testosterone (Neumann, 1971). Cyproterone acetate, however, with its marked progestational effect, inhibits the release of LH and FSH at the same time and thus has a lasting anti-androgenic effect (Neumann, 1970). Thus, cyproteron leads to an increase in LH, whereas cyproteron acetate inhibits both LH and FSH.
- ^ PMID 5091295.
- .
- PMID 206192.
Cyproterone (6-chloro-17a-hydroxy-1a,2a-methylene-pregna-4,6-diene-3,20-dione) and cyproterone acetate have received considerable attention as antispermatogenic substances. Cyproterone, which has·only weak antigonadotropic properties, was found to be a poor antispermatogenic agent (42). In contrast, cyproterone acetate, which inhibits gonadotropin secretion, was found to be an antispermatogenic agent (142).
- S2CID 43649686.
While CPA alone probably suppresses ovulation, cyproterone, which possesses no progestational activity, does not!8,72
- S2CID 11452300.
- PMID 9809473.
- ^ U.S. patent 3,234,093
- ISSN 0804-4643.
- PMID 5020316.
- ISBN 978-1-59259-152-7.
- PMID 4270254.
Free cyproterone was first tried as a therapy for precocious puberty by Bierich (1970, 1971). The results, however, did not show any significant improvement.
- ISBN 9780080175447.
[...] In this investigation a number of normal male volunteers were treated for three weeks with 100 mg free cyproterone per day. Sebum production was measured by the Straufi-Pochi method before treatment and on the 7th, 10th, 11th, 15th, 18th, [...]
- ISBN 978-0-87489-225-3.
Limited clinical experience also exists with benorterone, the first anti-androgen tried in man, and with free cyproterone. In the late sixties benorterone was reported to give promising results in 93 androgenized women but was soon withdrawn from clinical trial, mainly because of the development of gynaecomastia in the male. As a big advantage compared with CPA, it was found to be effective not only orally but also topically. Free cyproterone, on the other hand, proved to be without clinical value for reasons that cannot be discussed here. Thus we are left with CPA as the only anti-androgen that is already on the market in several countries.
Further reading
- Hughes A, Hasan SH, Oertel GW, Voss HE, Bahner F, Neumann F, et al. (27 November 2013). Androgens II and Antiandrogens / Androgene II und Antiandrogene. Springer Science & Business Media. pp. 241–545. ISBN 978-3-642-80859-3.